Three leading biopharmaceutical companies have
announced programs enabling employees with medical and laboratory
expertise to volunteer their services to local healthcare systems
and those hardest hit by COVID-19.
Merck & Co., Inc., (NYSE: MRK), Pfizer Inc. (NYSE: PFE), and
Eli Lilly and Company (NYSE: LLY) today announced medical service
volunteer programs to enable employees who are licensed medical
professionals to aid in the fight against COVID-19 while
maintaining their base pay.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20200401005708/en/
This new effort is one of the many ways that America’s
biopharmaceutical companies are coming together to fight COVID-19.
Together, these three major biopharmaceutical companies employ
thousands of doctors, nurses, pharmacists, medical laboratory
technicians and other medical professionals whose services are in
high demand during the COVID-19 pandemic. Some of these companies
are expanding their existing corporate volunteer programs so that
qualified employees who opt to serve can do so for a longer period
of time than normally allowed.
- Merck will support its employees around the world who are
uniquely qualified to provide medical services and wish to aid
communities affected by the COVID-19 pandemic. In the U.S., Merck
intends to collaborate with The Health Management Academy to
identify facilities with the greatest need and triage potential
qualifying volunteers to serve.
- Pfizer has created a new Global COVID-19 Medical Service
Program that empowers medical colleagues to provide diagnostic,
treatment, and public health support in the battle against
COVID-19. Licensed medical professionals who feel duty-bound to
provide their services during this crisis will now have a way to
engage in the fight against COVID-19. Colleagues will continue to
receive their full pay, benefits, and be able to return to their
position upon completion of service.
- Lilly is deploying its medical professionals to staff a free
drive-through COVID-19 testing facility at its corporate
headquarters in Indianapolis. The testing facility serves active
frontline health care workers and first responders, as a service to
the community and in an effort to protect people working on the
front lines of this pandemic. Lilly scientists are using the
company’s specialized research laboratories to analyze the tests,
as well as samples taken in Indiana health care facilities,
including nursing homes and emergency rooms, in partnership with
the Indiana State Department of Health. Lilly is also allowing
trained medical professionals to volunteer in service of
patients.
“COVID-19 is one of the greatest challenges the global community
will ever face, and our heroic health care professionals are,
unquestionably, on the front-lines of that fight,” said Kenneth C.
Frazier, chairman and chief executive officer, Merck. “We are
enormously grateful to them all, and it is our honor to be able to
support our own employee volunteers who are joining them in caring
for patients and communities affected by this pandemic.”
“At Pfizer, we employ some of the most dedicated and passionate
medical professionals who have devoted their lives to combating
disease and helping patients,” said Albert Bourla, chairman and
chief executive officer, Pfizer. “During this unprecedented global
health challenge, we are pursuing every option within Pfizer and
with external partners to help fight COVID-19. We believe that by
unleashing our medical professionals to help relieve some of the
burden being felt by hospitals, we can help make a real and
important difference. We support their wish to serve in this way
and are grateful for their courage and selflessness.”
“Right now the purpose of our industry has never been more clear
and vital – to bring the full force of our scientific and medical
expertise to attack this pandemic around the world,” said David A.
Ricks, chairman and chief executive officer, Lilly. “We’re honored
to join our industry partners in deploying our expert workforce to
help fight the virus, and our medical professionals stand ready to
volunteer. We’re working together – and with partners around the
world – to help our communities weather this storm and come back
even stronger.”
About Merck
For more than 125 years, Merck, known as MSD outside of the
United States and Canada, has been inventing for life, bringing
forward medicines and vaccines for many of the world’s most
challenging diseases in pursuit of our mission to save and improve
lives. We demonstrate our commitment to patients and population
health by increasing access to health care through far-reaching
policies, programs and partnerships. Today, Merck continues to be
at the forefront of research to prevent and treat diseases that
threaten people and animals – including cancer, infectious diseases
such as HIV and Ebola, and emerging animal diseases -- as we aspire
to be the premier research-intensive biopharmaceutical company in
the world. For more information, visit www.merck.com and connect
with us on Twitter, Facebook, Instagram, YouTube and LinkedIn.
Pfizer Inc.: Breakthroughs that change patients’
lives®
At Pfizer, we apply science and our global resources to bring
therapies to people that extend and significantly improve their
lives. We strive to set the standard for quality, safety and value
in the discovery, development and manufacture of health care
products, including innovative medicines and vaccines. Every day,
Pfizer colleagues work across developed and emerging markets to
advance wellness, prevention, treatments and cures that challenge
the most feared diseases of our time. Consistent with our
responsibility as one of the world's premier innovative
biopharmaceutical companies, we collaborate with health care
providers, governments and local communities to support and expand
access to reliable, affordable health care around the world. For
more than 150 years, we have worked to make a difference for all
who rely on us. We routinely post information that may be important
to investors on our website at www.pfizer.com. In addition, to
learn more, please visit us on www.pfizer.com and follow us on
Twitter at @Pfizer and @Pfizer_News, LinkedIn, YouTube and like us
on Facebook at Facebook.com/Pfizer.
About Eli Lilly and Company
Lilly is a global health care leader that unites caring with
discovery to create medicines that make life better for people
around the world. We were founded more than a century ago by a man
committed to creating high-quality medicines that meet real needs,
and today we remain true to that mission in all our work. Across
the globe, Lilly employees work to discover and bring life-changing
medicines to those who need them, improve the understanding and
management of disease, and give back to communities through
philanthropy and volunteerism. To learn more about Lilly, please
visit us at lilly.com and lilly.com/newsroom.
About The Health Management Academy
The Health Management Academy (The Academy) brings together
executives from leading health systems and partners to collectively
address the industry's biggest challenges and opportunities. The
Academy convenes executive peer-groups, provides world-class
leadership development programs, conducts targeted research, and
facilitates the development of strategic partnerships, in an effort
to support the most progressive organizations shaping the future of
healthcare. Visit academynet.com to learn more.
Forward-Looking Statement of Merck & Co., Inc.,
Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J.,
USA (the “company”) includes “forward-looking statements” within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. These statements are
based upon the current beliefs and expectations of the company’s
management and are subject to significant risks and uncertainties.
If underlying assumptions prove inaccurate or risks or
uncertainties materialize, actual results may differ materially
from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general
industry conditions and competition; general economic factors,
including interest rate and currency exchange rate fluctuations;
the impact of the recent global outbreak of novel coronavirus
disease (COVID-19); the impact of pharmaceutical industry
regulation and health care legislation in the United States and
internationally; global trends toward health care cost containment;
technological advances, new products and patents attained by
competitors; challenges inherent in new product development,
including obtaining regulatory approval; the company’s ability to
accurately predict future market conditions; manufacturing
difficulties or delays; financial instability of international
economies and sovereign risk; dependence on the effectiveness of
the company’s patents and other protections for innovative
products; and the exposure to litigation, including patent
litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause
results to differ materially from those described in the
forward-looking statements can be found in the company’s 2019
Annual Report on Form 10-K and the company’s other filings with the
Securities and Exchange Commission (SEC) available at the SEC’s
Internet site (www.sec.gov).
Pfizer Disclosure Notice
The information contained in this release is as of April 1,
2020. Pfizer assumes no obligation to update forward-looking
statements contained in this release as the result of new
information or future events or developments.
This release contains forward-looking information about Pfizer’s
efforts to battle COVID-19 that involves substantial risks and
uncertainties that could cause actual results to differ materially
from those expressed or implied by such statements. Risks and
uncertainties include, among other things, the uncertainties
inherent in research and development, including uncertainties
regarding the results of screening and the ability to meet
anticipated clinical endpoints, commencement and/or completion
dates for our clinical trials, regulatory submission dates,
regulatory approval dates and/or launch dates, as well as the
possibility of unfavorable pre-clinical or clinical data; the risk
that clinical trial data are subject to differing interpretations
and assessments by regulatory authorities; whether regulatory
authorities will be satisfied with the design of and results from
our clinical studies; whether and when drug applications for any
potential antiviral compounds may be filed or approved in any
jurisdictions, which will depend on myriad factors, including
making a determination as to whether the product's benefits
outweigh its known risks and determination of the product's
efficacy; decisions by regulatory authorities impacting labeling,
manufacturing processes, safety and/or other matters that could
affect the availability or commercial potential of any such
products; our manufacturing capabilities; and competitive
developments. A further description of risks and uncertainties can
be found in Pfizer's Annual Report on Form 10- K for the fiscal
year ended December 31, 2019 and in its subsequent reports on Form
10-Q, including in the sections thereof captioned "Risk Factors"
and "Forward-Looking Information and Factors That May Affect Future
Results", as well as in its subsequent reports on Form 8-K, all of
which are filed with the U.S. Securities and Exchange Commission
and available at www.sec.gov and www.pfizer.com.
Forward-Looking Statement of Eli Lilly and Company,
Indianapolis, Ind., USA
This release contains forward-looking statements regarding
Lilly’s efforts in regard to the novel coronavirus. These
statements are based on management's current expectations, but
actual results may differ materially. Other risk factors that may
affect the company's results can be found in the company's latest
Forms 10-K and 10-Q filed with the U.S. Securities and Exchange
Commission. Lilly undertakes no duty to update forward-looking
statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200401005708/en/
Patrick Ryan, Merck (201) 452-2409
Sally Beatty, Pfizer (347) 330-7867
Scott MacGregor, Eli Lilly (317) 440-4699
Merck (NYSE:MRK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Apr 2023 to Apr 2024